Zarina Sabirova, Shazia Mahnoor, Dina Lasfar, Vincent Gagné, Yves Théorêt, Jean Marie Leclerc, Caroline Laverdière, Daniel Sinnett, Thai-Hoa Tran, Maja Krajinovic
Acute lymphoblastic leukemia (ALL) is the most frequent pediatric cancer. 6-Mercaptopurine (6-MP) is a key component of ALL treatment. Its use, however, is also associated with adverse drug reactions, particularly myelosuppression. Thiopurine S-methyltransferase (TPMT) and, more recently, Nudix hydrolase 15 (NUDT15) deficiency, due to no-function variants in their respective genes, are well known for their role in the development of this toxicity. Two novel genetic variants, rs12199316 in TPMT and rs73189762 in the NUDT15 gene, were recently identified by targeted sequencing...
April 15, 2024: Pharmacogenetics and Genomics